Giona Sonego
Overview
Explore the profile of Giona Sonego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sonego G, Le T, Crettaz D, Abonnenc M, Tissot J, Prudent M
J Thromb Haemost
. 2020 Oct;
19(1):233-247.
PMID: 33047470
Essentials Cysteine oxidation to sulfenic acid plays a key role in redox regulation and signal transduction. Platelet sulfenylome was studied by quantitative proteomics in pathogen inactivated platelets. One hundred and...
2.
Sonego G, Abonnenc M, Tissot J, Prudent M, Lion N
Int J Mol Sci
. 2017 Feb;
18(2).
PMID: 28208668
Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs, but the underlying...
3.
Abonnenc M, Crettaz D, Tacchini P, Di Vincenzo L, Sonego G, Prudent M, et al.
Transfusion
. 2016 May;
56(7):1819-27.
PMID: 27184608
Background: Pathogen inactivation treatments such as INTERCEPT aim to make sure blood and blood-derived products are free of pathogens before using them for transfusion purposes. At present, there is no...
4.
Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot J, et al.
Transfusion
. 2015 Apr;
55(9):2219-30.
PMID: 25873361
Background: Platelet inactivation technologies (PITs) have been shown to increase platelet storage lesions (PSLs). This study investigates amotosalen/ultraviolet (UV)A- and riboflavin/UVB-induced platelet (PLT) lesions in vitro. Particular attention is given...
5.
Abonnenc M, Sonego G, Kaiser-Guignard J, Crettaz D, Prudent M, Tissot J, et al.
Blood Transfus
. 2014 Nov;
13(2):255-64.
PMID: 25369598
Background: The Intercept Blood SystemTM (Cerus) is used to inactivate pathogens in platelet concentrates (PC). The aim of this study was to elucidate the extent to which the Intercept treatment...
6.
Prudent M, Sonego G, Abonnenc M, Tissot J, Lion N
J Am Soc Mass Spectrom
. 2014 Jan;
25(4):651-61.
PMID: 24470194
Pathogen reduction technologies (PRT) are photochemical processes that use a combination of photosensitizers and UV-light to inactivate pathogens in platelet concentrates (PCs), a blood-derived product used to prevent hemorrhage. However,...